GenVec to Release Fourth Quarter and Year-End 2014 Financial Results and Conduct a Conference Call on March 24, 2015

GAITHERSBURG, Md., March 17, 2015 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) will report financial results for the fourth quarter and year ended December 31, 2014 on Tuesday, March 24, 2015, before the U.S. financial markets open. The company's press release will be followed by a webcast conference call at 10:00 a.m. EDT to discuss GenVec's fourth quarter and 2014 financial results and 2015 business outlook.

To listen to the live conference call, please dial 877-359-9508 (U.S. or Canada) or 224-357-2393 (international) and use the following Conference ID: 93345116. An audio replay of the conference call will be available starting at Noon EDT on March 24, 2015 and will be available through March 31, 2015. To listen to the audio replay, dial 855-859-2056 or 404-537-3406 and use Conference Replay ID: 93345116.

To access the audio webcast or the replay, go to www.genvec.com, click on the "Investors and Media" tab, scroll down to News/Events and click open the Presentations collection.   The archived replay will be available for 90 days.

About GenVec

GenVec is an entrepreneurial clinical-stage biopharmaceutical company focused on leveraging its proprietary adenovector gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product, CGF166, is licensed to Novartis and currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, the company also licenses its proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

Contact:        
GenVec, Inc.                          
Rena Cohen               
(240) 632-5501                      
[email protected]

SOURCE GenVec, Inc.

Related Links

http://www.genvec.com